[AI generated Pharma News]

• Turbine's Virtual Lab: The Hungary-based firm raised $25 million to scale its AI platform that simulates cellular biology to accelerate drug discovery.
• Global Licensing Surges: Highlighting Chinese expansion, Frontier signed a $1 billion kidney disease deal with GSK, while Harbour BioMed penned a $1.2 billion cancer treatment agreement with Solstice.
• Astellas & Vir Partnership: A $1.7 billion collaboration focuses on VIR-5500, a prostate cancer therapy that demonstrated a 45% response rate in early trials.